| An inhibitor of oxidative phosphorylation exploits cancer vulnerability JR Molina, Y Sun, M Protopopova, S Gera, M Bandi, C Bristow, T McAfoos, ... Nature medicine 24 (7), 1036-1046, 2018 | 748 | 2018 |
| Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, ... Blood, The Journal of the American Society of Hematology 135 (11), 791-803, 2020 | 494 | 2020 |
| A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ... Nature medicine 25 (12), 1938-1947, 2019 | 442 | 2019 |
| Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, ... Nature medicine 29 (1), 115-126, 2023 | 118 | 2023 |
| Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models RS Mali, Q Zhang, RA DeFilippis, A Cavazos, VM Kuruvilla, J Raman, ... Haematologica 106 (4), 1034, 2021 | 101 | 2021 |
| Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models L Han, Q Zhang, M Dail, C Shi, A Cavazos, VR Ruvolo, Y Zhao, E Kim, ... Haematologica 105 (3), 697, 2020 | 99 | 2020 |
| Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ... Nature communications 12 (1), 6896, 2021 | 85 | 2021 |
| Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, ... Signal transduction and targeted therapy 7 (1), 51, 2022 | 81 | 2022 |
| Disruption of Wnt/β-catenin exerts antileukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia X Jiang, PY Mak, H Mu, W Tao, DH Mak, S Kornblau, Q Zhang, P Ruvolo, ... Clinical Cancer Research 24 (10), 2417-2429, 2018 | 80 | 2018 |
| A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies DC Phillips, S Jin, GP Gregory, Q Zhang, J Xue, X Zhao, J Chen, Y Tong, ... Leukemia 34 (6), 1646-1657, 2020 | 67 | 2020 |
| Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD T Yuan, Y Yang, J Chen, W Li, Q Zhang, Y Mi, RS Goswami, JQ You, ... Leukemia 31 (11), 2355-2364, 2017 | 62 | 2017 |
| Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell … Q Zhang, C Shi, L Han, N Jain, KG Roberts, H Ma, T Cai, A Cavazos, ... Oncotarget 9 (8), 8027, 2018 | 51 | 2018 |
| Antileukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody conjugate, in acute myeloid leukemia L Han, JL Jorgensen, C Brooks, C Shi, Q Zhang, GM Nogueras González, ... Clinical Cancer Research 23 (13), 3385-3395, 2017 | 45 | 2017 |
| Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition K Saito, Q Zhang, H Yang, K Yamatani, T Ai, V Ruvolo, N Baran, T Cai, ... Blood advances 5 (20), 4233-4255, 2021 | 44 | 2021 |
| Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia H Kuusanmäki, O Dufva, M Vähä-Koskela, AM Leppä, J Huuhtanen, ... Blood 141 (13), 1610-1625, 2023 | 42 | 2023 |
| MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells Z Zeng, RY Wang, YH Qiu, DH Mak, K Coombes, SY Yoo, Q Zhang, ... Oncotarget 7 (34), 55083, 2016 | 34 | 2016 |
| Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells T Cai, A Gouble, KL Black, A Skwarska, AS Naqvi, D Taylor, M Zhao, ... Nature communications 13 (1), 2228, 2022 | 26 | 2022 |
| Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia L Zhang, T Cai, X Lin, X Huang, MH Bui, JP Plotnik, RJ Bellin, EJ Faivre, ... Molecular cancer therapeutics 20 (10), 1809-1819, 2021 | 24 | 2021 |
| Interim analysis of phase II study of venetoclax with 10-day decitabine (DEC10-VEN) in acute myeloid leukemia and myelodysplastic syndrome A Maiti, CD DiNardo, JE Cortes, G Borthakur, N Pemmaraju, CB Benton, ... Blood 132, 286, 2018 | 24 | 2018 |
| Ten-day decitabine with venetoclax (DEC10-VEN) in acute myeloid leukemia: updated results of a phase II trial A Maiti, CD DiNardo, CR Rausch, JE Cortes, N Pemmaraju, NG Daver, ... Blood 134, 2637, 2019 | 21 | 2019 |
Michael AndreeffUT MD Anderson Cancer Center在 mdanderson.org 的电子邮件经过验证
